171 related articles for article (PubMed ID: 28653881)
1. Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.
Shen Y; Sun Y; Zhang L; Liu H
Tumour Biol; 2017 Jun; 39(6):1010428317703941. PubMed ID: 28653881
[TBL] [Abstract][Full Text] [Related]
2. The role of Capon in multiple myeloma.
Shen Y; Liu H; Gu S; Wei Z; Liu H
Tumour Biol; 2017 Jul; 39(7):1010428317713674. PubMed ID: 28671047
[TBL] [Abstract][Full Text] [Related]
3. RBQ3 participates in multiple myeloma cell proliferation, adhesion and chemoresistance.
Liu H; Ding L; Shen Y; Zhong F; Wang Q; Xu X
Int J Biol Macromol; 2016 Oct; 91():115-22. PubMed ID: 27189701
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
5. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
[TBL] [Abstract][Full Text] [Related]
6. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells.
Nakamura S; Kobayashi M; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Hayashi H; Ohnishi K
Leuk Res; 2006 Feb; 30(2):123-35. PubMed ID: 16046235
[TBL] [Abstract][Full Text] [Related]
7. EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma.
Ding L; Shen Y; Ni J; Ou Y; Ou Y; Liu H
Tumour Biol; 2017 Mar; 39(3):1010428317694298. PubMed ID: 28351297
[TBL] [Abstract][Full Text] [Related]
8. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
[TBL] [Abstract][Full Text] [Related]
9. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
10. PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.
Azab F; Vali S; Abraham J; Potter N; Muz B; de la Puente P; Fiala M; Paasch J; Sultana Z; Tyagi A; Abbasi T; Vij R; Azab AK
Br J Haematol; 2014 Apr; 165(1):89-101. PubMed ID: 24405121
[TBL] [Abstract][Full Text] [Related]
11. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.
Holien T; Olsen OE; Misund K; Hella H; Waage A; Rø TB; Sundan A
Eur J Haematol; 2013 Oct; 91(4):339-46. PubMed ID: 23869695
[TBL] [Abstract][Full Text] [Related]
12. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
14. Role of RACK1 on cell proliferation, adhesion, and bortezomib-induced apoptosis in multiple myeloma.
Zhang L; Xu Y; Wang L; Liu H
Int J Biol Macromol; 2019 Jan; 121():1077-1085. PubMed ID: 30315883
[TBL] [Abstract][Full Text] [Related]
15. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
Xu P; Jiang YF; Wang JH
Int J Clin Exp Pathol; 2015; 8(3):2300-10. PubMed ID: 26045737
[TBL] [Abstract][Full Text] [Related]
16. [Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells].
Zang MR; Li F; An G; Xie ZQ; Li CH; Yu Z; Xu Y; Qiu LG; Hao M
Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(16):1100-3. PubMed ID: 22781767
[TBL] [Abstract][Full Text] [Related]
17. ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib.
Wu SQ; Xu ZZ; Niu WY; Huang HB; Zhan R
Int J Mol Med; 2014 Aug; 34(2):616-23. PubMed ID: 24913180
[TBL] [Abstract][Full Text] [Related]
18. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M
Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro.
Que W; Chen J
Mol Med Rep; 2011; 4(2):343-9. PubMed ID: 21468575
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
